These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29261716)

  • 1. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.
    Lee SR; Choi EK; Han KD; Cha MJ; Oh S; Lip GYH
    PLoS One; 2017; 12(12):e0189495. PubMed ID: 29261716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study.
    Park J; Choi EK; Han KD; Choi YJ; Lee E; Choe W; Lee SR; Cha MJ; Lim WH; Kang J; Park KW; Oh S; Lip GYH
    PLoS One; 2019; 14(1):e0209593. PubMed ID: 30645601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk" Patients?
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Curr Drug Targets; 2017 Nov; 18(16):1852-1865. PubMed ID: 27593686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal Trends in Pharmacological Stroke Prevention in Patients with Acute Ischemic Stroke and Known Atrial Fibrillation.
    Hellwig S; Grittner U; Herm J; Ruschmann R; Konieczny M; Endres M; Haeusler KG
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105266. PubMed ID: 32992191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic Therapy in Atrial Fibrillation Management in Western Australia: Temporal Trends and Evidence-Treatment Gaps.
    Hutchens R; Hung J; Briffa T; McQuillan B
    Heart Lung Circ; 2021 Jul; 30(7):955-962. PubMed ID: 33386242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
    Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
    BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
    Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
    Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.